The First Drug Approved for OSA
GLP-1s andsleep apnea
In December 2024 the FDA approved Zepbound (tirzepatide) for obstructive sleep apnea with obesity — the first drug ever approved specifically for OSA. Here's what GLP-1s can do, what they can't, and how to sequence them with CPAP.
Medically reviewed by the board-certified sleep physicians at Nocturne Health · Last updated July 2026
Short answer: real effect, real limits, don't stop CPAP unilaterally
Medically reviewed by the Nocturne Health clinical team · Last updated July 6, 2026
GLP-1 receptor agonists — Zepbound and Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide) — reduce obstructive sleep apnea severity because they produce sustained weight loss, and weight loss reduces the fat around the neck and abdomen that causes most airway collapse. In the SURMOUNT-OSA trial published in the New England Journal of Medicine in 2024, tirzepatide reduced the apnea–hypopnea index by roughly 27–30 events per hour over 52 weeks, and about half of participants reached disease resolution. That's a large clinical effect. But roughly half did not resolve — meaning weight loss is not a guaranteed cure, and stopping CPAP without a follow-up sleep study is a bet against your own airway.
How GLP-1s actually help sleep apnea
The mechanism is almost entirely weight-loss-mediated. GLP-1s do not directly stabilize the airway; they change the tissue around it:
- Sustained weight loss reduces fat around the neck, throat, and tongue — the mechanical cause of airway collapse in most obstructive sleep apnea
- Abdominal fat loss improves lung volume overnight, which mechanically supports the upper airway
- In the SURMOUNT-OSA trial, tirzepatide reduced the apnea–hypopnea index by roughly 27–30 events per hour on average — a large clinical effect
- About half of trial participants reached the threshold of disease resolution (AHI under 5, or 5–14 without symptoms) after 52 weeks
This is why the FDA approval for Zepbound is specifically for OSA in adults with obesity— the mechanism requires meaningful weight loss to be there.
What GLP-1s do not do
Two things to hold in your head at the same time: this is the biggest advance in OSA treatment in years, and it does not replace an accurate diagnosis or CPAP:
- It does not resolve sleep apnea overnight — weight loss is gradual and takes 6–12+ months to produce meaningful airway change
- It does not fix non-weight-related causes of OSA — narrow airway anatomy, large tonsils, jaw structure, or central apnea
- It is not a substitute for CPAP or an oral appliance while your OSA remains untreated — untreated apnea keeps stressing your cardiovascular system every night
- It does not automatically make it safe to stop treatment — that decision needs a follow-up sleep study, not a scale
About half of tirzepatide-arm participants in SURMOUNT-OSA did not reach disease resolution even after 52 weeks and an average ~18–20% body-weight loss. Airway anatomy varies — weight loss alone doesn't override every case.
How to sequence a GLP-1 with CPAP or other treatment
The mistake we see most often is patients stopping CPAP once they start losing weight, then spending months back in untreated apnea. Better sequence:
- Get an accurate diagnosis first with a home sleep apnea test, so you know your starting AHI and severity
- Start CPAP, an oral appliance, or another appropriate treatment while your weight loss plan runs — don't spend months untreated
- Track weight loss and symptoms with your prescribing clinician; retesting typically makes sense after roughly 10%+ sustained body-weight loss or 6–12 months of therapy
- Repeat the home sleep test to measure the new AHI — some patients can wean off CPAP; many still need it at a lower pressure; a minority see minimal AHI change
Many patients do successfully wean off CPAP after significant sustained weight loss. Some drop to a lower pressure. Some still need CPAP indefinitely. The only honest way to know which you'll be is a follow-up sleep study, not a bathroom scale.
Diagnosis first — even if you're already on a GLP-1
If you suspect sleep apnea and are already on a GLP-1 for weight loss or diabetes, don't skip the diagnostic step. Insurers increasingly cover Zepbound for OSA specifically since the December 2024 approval, but coverage typically requires documented moderate-to-severe OSA — usually from a sleep study. And regardless of drug coverage, knowing your baseline AHI is what lets you measure whether the drug is doing what you're paying for it to do.
At Nocturne Health you can order an FDA-approved home sleep apnea test as a standalone service ($169) — a physician reviews your intake and orders it, and your report is emailed to you, typically within 72 hours. A full $199 consultation is available if you'd rather map out the weight-loss + CPAP sequence with a sleep physician first. Related reading: sleep apnea and weight and CPAP alternatives.
Measure the drug's effect on your actual airway
Order a physician-supervised home sleep apnea test ($169) or book a $199 visit with a board-certified sleep physician. Available to patients in Arkansas, California, Massachusetts, Missouri, Ohio, Oklahoma, and Pennsylvania.
GLP-1s and sleep apnea: common questions
Can I take Zepbound (tirzepatide) for sleep apnea?
In December 2024 the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved specifically for OSA. Approval was based on the SURMOUNT-OSA trial, which showed roughly a 27–30 event-per-hour reduction in the apnea–hypopnea index over 52 weeks and disease resolution in about half of participants. Whether you personally qualify depends on your BMI, diagnosis, and other clinical factors.
Do Ozempic, Wegovy, or Mounjaro treat sleep apnea?
Not officially, but the mechanism overlaps. Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide, the same molecule as Zepbound but a different indication) both produce meaningful weight loss, and weight loss is one of the most effective non-CPAP interventions for obstructive sleep apnea. Only Zepbound is FDA-approved specifically for OSA, but many patients on any of these drugs will see apnea severity improve as they lose weight.
Can I stop CPAP now that I'm on a GLP-1?
Not without a follow-up sleep study. Weight loss on a GLP-1 is gradual, and even significant weight loss does not always resolve sleep apnea — airway anatomy, jaw structure, and non-weight factors still matter. Stopping CPAP prematurely means going back to unmanaged nightly oxygen drops and cardiovascular strain. Talk to a sleep physician about a repeat home sleep test after roughly 10%+ sustained weight loss to see where your AHI actually lands.
How much weight loss do I need before I might come off CPAP?
There is no single threshold, but the clinical trial data and AASM guidance point to roughly 10% or more of sustained body-weight loss as the point where OSA severity meaningfully shifts. In the SURMOUNT-OSA trial the tirzepatide arm lost about 18–20% of body weight on average. About half of participants reached disease resolution — meaning half did not, even at that magnitude of weight loss. A repeat sleep study is the only honest way to know.
Will insurance cover Zepbound for sleep apnea?
Coverage varies. Since the December 2024 FDA approval, some Medicare Part D plans and commercial insurers cover Zepbound when prescribed for moderate-to-severe OSA in patients with obesity — a shift from earlier coverage that only applied to weight-loss indications. You'll need a documented diagnosis, typically from a sleep study, and often a specific BMI threshold. Nocturne Health can order the home sleep test and provide the diagnostic documentation your prescriber needs.
I started a GLP-1 and my snoring got worse — what's happening?
It's uncommon for weight loss to worsen OSA, but a few things can cause new sleep complaints on a GLP-1: reflux (a known side effect that can disrupt sleep and irritate the airway), medication-related nausea, and dose-titration changes. If snoring, choking, or witnessed apneas are new or worse, it's worth being evaluated rather than waiting for weight loss to eventually catch up.
References
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine, 2024.
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound). December 20, 2024.
- Kapur VK, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, AASM, 2017.